AI for Newborn Metabolic Screening

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age2-28
SponsorThe Children's Hospital of Zhejiang University School of Medicine

About this trial

The goal of this clinical trial is to evaluate whether an artificial intelligence (AI)-based interpretation system can accurately diagnose inherited metabolic disorders in newborns undergoing routine screening. The main questions it aims to answer are:

What is the sensitivity and specificity of the AI system compared to standard manual interpretation? Does the AI system reduce variability in screening results? Researchers will compare the AI interpretation results with those from standard manual review by trained laboratory staff to assess diagnostic performance.

Participants will:

Have their routine newborn screening blood samples analyzed using both the AI system and standard manual interpretation Be followed according to national newborn screening guidelines if either method indicates a positive result

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Newborns who underwent routine newborn screening for inherited metabolic disorders at the Zhejiang Provincial Newborn Screening Center between May 2025 and December 2027

Blood samples collected between 2 and 28 days of age

Availability of complete newborn screening test data and essential clinical information

Disqualifiers

Missing, incomplete, or poor-quality screening data

Duplicate samples from the same newborn

Trial design

Design model

Single group

Treatments tested in this trial

  • Artificial intelligence-based interpretation system for newborn genetic metabolic disease screening

    Diagnostic test

    This intervention is a deep learning-based software algorithm designed specifically for the interpretation of tandem mass spectrometry (MS/MS) data from routine newborn screening in Chinese neonates. It integrates clinical covariates-including gestational age, birth weight, and blood collection time-to perform multiple-of-the-median (MOM) normalization and simultaneously evaluates 42 inherited metabolic disorders. Unlike existing AI tools developed for older-generation screening panels (e.g., those covering only 29 analytes), this system is trained and validated on over 300,000 real-world Chinese newborn samples, making it the first AI diagnostic tool tailored to China's current expanded newborn screening program.

Treatment groups

200,000 Participants
are divided into 1 treatment group
Group A: AI and Manual Interpretation of Newborn Screening DataOther 1 intervention

Trial outcomes

Primary outcomes

1

Sensitivity of the AI interpretation system for detecting inherited metabolic disorders

Time frame
Within 12 months after newborn screening
2

Specificity of the AI interpretation system for detecting inherited metabolic disorders

Time frame
Within 12 months after newborn screening

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: